These included gallbladder cancer (HR = 0.35), meningioma (HR = 0.37), pancreatic cancer (HR = 0.41), hepatocellular carcinoma (HR = 0.47), ovarian cancer (HR = 0.52), colorectal cancer (HR = 0.54), multiple myeloma (HR = 0.59), esophageal cancer (HR = 0.60), endometrial cancer (HR = 0.74), and kidney cancer (HR = 0.76)
Incorrect coding leads to claim rejections and financial losses
Approved for weight management as Saxenda, it requires daily injections rather than weekly, which is a significant practical difference
For more information on Melanotan 2 peptide please visit Wikipedia
The approval supports evidence that GLP-1 drugs improve overall health along with weight loss
The challenge here is that reducing the risk of future adverse outcomes cannot be measured in the present of any particular patient